Symbravo Generic: When Will Generic Meloxicam and Rizatriptan Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Symbravo Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? May 2040 About 13.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? March 2045 96 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic meloxicam and rizatriptan is expected to be available in May 2040, about 13.5 years away. None is for sale yet.
Why May 2040?
It is when Symbravo’s patent 12,128,052 ends. That patent covers a way of using it, and once it ends, generics should be able to go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
If Symbravo’s last patent runs to March 2045, how can a generic come sooner?
The 4 patents that run past the expected month, to March 2045 (12,370,196, 12,611,413, 12,005,118 and 12,544,383), cover a way of using it. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Generic companies have been challenging Symbravo’s patents with the FDA since June 2025. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic, which would take the $122.64 pharmacies pay per tablet for Symbravo today to about $84.62. See the price estimate
What should I do now?
Keep taking Symbravo as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Symbravo by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Low 1 company has filed, 1 first in line
- Brand sales
- Sales not reported
- FDA approved 2025 January 2025 FDA Orange Book
- Patents listed 96 last runs to March 2045 A generic is expected sooner, in May 2040. See why FDA Orange Book
- Pharmacies pay $122.64 per tablet NADAC, October 2026
- Medicare Part D spent $1.7M in 2025, for 568 people CMS Part D Spending by Drug
- Medicaid prescriptions 3,241 in the last four reported quarters, $3.6M CMS Medicaid drug utilization, to Q1 2026
Symbravo’s Road to a Generic
Symbravo has had the market to itself since the FDA approved it in January 2025 (Axsome Therapeutics Inc). Its FDA protection (new product) runs to January 2028. Its 96 listed patents run to March 2045. Generic companies have challenged its patents with the FDA since June 2025.
The first generic of Symbravo is expected in May 2040.
Why that month: patent 12,128,052, on a way of using it, ends then. That is about 5 years before the last listed patent runs out, in March 2045.
Why a Generic Can Come Before March 2045
The last listed patent runs to March 2045, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Symbravo Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Symbravo’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 12,128,052, which ends in May 2040, the month the first generic is expected. Why the later ones may not hold it back
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 9,821,075 | The product’s formulation; a way of using it (U-1719) | April 2036 | Active |
| 10,029,010 | A way of using it (U-4133) | April 2036 | Active |
| 10,058,614 | The product’s formulation | April 2036 | Active |
| 10,137,131 | The product’s formulation; a way of using it (U-1719) | April 2036 | Active |
| 10,195,278 | A way of using it (U-1719) | April 2036 | Active |
| 10,265,324 | A way of using it (U-1719) | April 2036 | Active |
| 10,265,399 | A way of using it (U-4509) | April 2036 | Active |
| 10,265,400 | A way of using it (U-4509) | April 2036 | Active |
| 10,307,484 | A way of using it (U-4509) | April 2036 | Active |
| 10,363,312 | A way of using it (U-1719) | April 2036 | Active |
| 10,369,224 | A way of using it (U-4134) | April 2036 | Active |
| 10,369,225 | A way of using it (U-4356) | April 2036 | Active |
| 10,426,839 | A way of using it (U-4135) | April 2036 | Active |
| 10,456,471 | A way of using it (U-4509) | April 2036 | Active |
| 10,463,736 | The product’s formulation | April 2036 | Active |
| 10,471,014 | A way of using it (U-1719) | April 2036 | Active |
| 10,471,069 | A way of using it (U-1719) | April 2036 | Active |
| 10,512,692 | A way of using it (U-1719) | April 2036 | Active |
| 10,512,693 | A way of using it (U-1719) | April 2036 | Active |
| 10,517,950 | A way of using it (U-1719) | April 2036 | Active |
| 10,532,101 | A way of using it (U-1719) | April 2036 | Active |
| 10,537,642 | A way of using it (U-1719) | April 2036 | Active |
| 10,561,664 | A way of using it (U-1719) | April 2036 | Active |
| 10,583,144 | A way of using it (U-1719) | April 2036 | Active |
| 10,653,777 | A way of using it (U-1719) | April 2036 | Active |
| 10,688,102 | A way of using it (U-1719) | April 2036 | Active |
| 10,688,185 | A way of using it (U-1719) | April 2036 | Active |
| 10,695,429 | A way of using it (U-1719) | April 2036 | Active |
| 10,695,430 | A way of using it (U-1719) | April 2036 | Active |
| 10,702,535 | A way of using it (U-4136) | April 2036 | Active |
| 10,702,602 | A way of using it (U-1719) | April 2036 | Active |
| 10,722,583 | A way of using it (U-1719) | April 2036 | Active |
| 10,729,696 | A way of using it (U-1719) | April 2036 | Active |
| 10,729,697 | A way of using it (U-1719) | April 2036 | Active |
| 10,729,773 | A way of using it (U-1719) | April 2036 | Active |
| 10,758,617 | A way of using it (U-1719) | April 2036 | Active |
| 10,758,618 | A way of using it (U-1719) | April 2036 | Active |
| 10,780,165 | A way of using it (U-1719) | April 2036 | Active |
| 10,780,166 | A way of using it (U-1719) | April 2036 | Active |
| 10,799,588 | A way of using it (U-1719) | April 2036 | Active |
| 10,821,181 | A way of using it (U-1719) | April 2036 | Active |
| 10,821,182 | A way of using it (U-1719) | April 2036 | Active |
| 10,894,053 | A way of using it (U-1719) | April 2036 | Active |
| 10,905,693 | A way of using it (U-1719) | April 2036 | Active |
| 10,918,722 | A way of using it (U-1719) | April 2036 | Active |
| 10,933,136 | A way of using it (U-1719) | April 2036 | Active |
| 10,933,137 | A way of using it (U-1719) | April 2036 | Active |
| 10,940,153 | A way of using it (U-1719) | April 2036 | Active |
| 10,987,358 | A way of using it (U-1719) | April 2036 | Active |
| 11,013,805 | A way of using it (U-1719) | April 2036 | Active |
| 11,013,806 | A way of using it (U-1719) | April 2036 | Active |
| 11,020,483 | A way of using it (U-1719) | April 2036 | Active |
| 11,045,549 | A way of using it (U-1719) | April 2036 | Active |
| 11,135,295 | A way of using it (U-1719) | April 2036 | Active |
| 11,207,328 | A way of using it (U-1719) | April 2036 | Active |
| 11,219,626 | A way of using it (U-1719) | April 2036 | Active |
| 11,266,657 | A way of using it (U-1719) | April 2036 | Active |
| 11,285,213 | A way of using it (U-1719) | April 2036 | Active |
| 11,331,323 | A way of using it (U-1719) | April 2036 | Active |
| 11,369,684 | A way of using it (U-1719) | April 2036 | Active |
| 11,426,414 | A way of using it (U-1719) | April 2036 | Active |
| 11,433,078 | A way of using it (U-1719) | April 2036 | Active |
| 11,433,079 | A way of using it (U-1719) | April 2036 | Active |
| 11,471,464 | A way of using it (U-1719) | April 2036 | Active |
| 11,471,465 | A way of using it (U-1719) | April 2036 | Active |
| 11,504,429 | A way of using it (U-1719) | April 2036 | Active |
| 11,510,927 | A way of using it (U-1719) | April 2036 | Active |
| 11,571,428 | A way of using it (U-1719) | April 2036 | Active |
| 11,602,563 | A way of using it (U-1719) | April 2036 | Active |
| 11,607,456 | A way of using it (U-1719) | April 2036 | Active |
| 11,617,755 | A way of using it (U-1719) | April 2036 | Active |
| 11,617,756 | A way of using it (U-1719) | April 2036 | Active |
| 11,617,791 | A way of using it (U-1719) | April 2036 | Active |
| 11,628,173 | A way of using it (U-1719) | April 2036 | Active |
| 11,712,441 | A way of using it (U-1719) | April 2036 | Active |
| 11,738,085 | A way of using it (U-1719) | April 2036 | Active |
| 11,759,522 | A way of using it (U-1719) | April 2036 | Active |
| 11,801,250 | A way of using it (U-1719) | April 2036 | Active |
| 11,806,354 | A way of using it (U-1719) | April 2036 | Active |
| 11,826,370 | A way of using it (U-1719) | April 2036 | Active |
| 11,865,117 | A way of using it (U-1719) | April 2036 | Active |
| 11,944,683 | A way of using it (U-1719) | April 2036 | Active |
| 12,485,176 | A way of using it (U-4133) | April 2036 | Active |
| 12,691,123 | A way of using it (U-1719) | April 2036 | Active |
| 12,472,256 | A way of using it (U-4356) | May 2038 | Active |
| 12,472,257 | A way of using it (U-4134) | May 2038 | Active |
| 12,472,258 | The product’s formulation | May 2038 | Active |
| 12,616,752 | A way of using it (U-4510) | May 2038 | Active |
| 12,685,736 | A way of using it (U-1719) | May 2040 | Active |
| 12,128,052 Sets the expected month of generic availability | A way of using it (U-1719) | May 2040 | Active |
| 12,551,488 | A way of using it (U-1719) | May 2040 | Active |
| 12,551,489 | A way of using it (U-1719) | May 2040 | Active |
| 12,370,196 | A way of using it (U-1719) | December 2041 | Active |
| 12,611,413 | A way of using it (U-1719) | December 2041 | Active |
| 12,005,118 | A way of using it (U-1719) | January 2043 | Active |
| 12,544,383 | A way of using it (U-1719) | March 2045 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New product NP | Three years of protection for a change that needed new clinical studies. | January 2028 | Active |
Source: FDA Orange Book, application 215431. Patent numbers open the patent on Google Patents.
Patent Challenges to Symbravo
The first patent challenge to Symbravo reached the FDA in June 2025, from one company on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Symbravo’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Tablets, 20 mg/10 mg | June 2025 | 1 company | No decision yet | Not yet | Not yet | May 2040 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Meloxicam and Rizatriptan
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
One company has applied to the FDA to make generic meloxicam and rizatriptan.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for this one yet, so the company is not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Symbravo’s patents with the FDA since June 2025: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic meloxicam and rizatriptan. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic meloxicam and rizatriptan for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Symbravo Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Symbravo 20-10 mg tablet
$122.64 per tablet in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $122.64 |
| September 2026 | $122.64 |
| August 2026 | $122.70 |
| July 2026 | $122.67 |
| June 2026 | $122.68 |
| May 2026 | $122.69 |
| April 2026 | $122.72 |
| March 2026 | $122.76 |
| February 2026 | $122.76 |
| January 2026 | $122.75 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Symbravo today: $122.64 per tablet for Symbravo 20-10 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017). Symbravo has one company lined up, so our estimate uses the figure for one company. More companies would bring the price lower; fewer, less of a drop.
Dollar figures apply FDA’s median drops to the $122.64 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Symbravo
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Symbravo, before manufacturer rebates.
- $1.2M
- January to March 2026, the latest CMS has posted
For 533 people, about $1,239 per prescription fill - $1.7M
- 2025, the whole year
For 568 people, about $1,220 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $1,181,597 | 533 | $1,238.57 |
| 2025 | $1,655,180 | 568 | $1,219.74 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Symbravo only, so no generic is counted in it. What CMS says it is used for: This combination medication contains two ingredients: rizatriptan and meloxicam. It helps to relieve headache, pain, and other migraine symptoms (such as nausea, vomiting, sensitivity to light/sound).
Medicaid Prescriptions by Quarter
3,241 prescriptions in the four quarters to Q1 2026, $3.6M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 1,540 | $1,705,459 |
| Q4 2025 | 1,201 | $1,335,622 |
| Q3 2025 | 485 | $544,335 |
| Q2 2025 | 15 | $17,391 |
Source: CMS Medicaid State Drug Utilization Data, over Symbravo’s own package codes.
Symbravo Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 20MG;EQ 10MG BASE | Tablet | Oral | January 2025 | Prescription reference product |
Source: FDA Orange Book, Axsome Therapeutics Inc. Listed for sale today by Axsome Therapeutics, Inc. (FDA NDC Directory).
Symbravo NDC Codes and Packages
Each Symbravo package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 81968-0020-02 | MELOXICAM 20 mg/1 / RIZATRIPTAN BENZOATE 10 mg/1 tablet | bottle of 2 tablets | Axsome Therapeutics, Inc. |
| 81968-0020-03 | MELOXICAM 20 mg/1 / RIZATRIPTAN BENZOATE 10 mg/1 tablet | bottle of 3 tablets | Axsome Therapeutics, Inc. |
| 81968-0020-09 | MELOXICAM 20 mg/1 / RIZATRIPTAN BENZOATE 10 mg/1 tablet | bottle of 9 tablets | Axsome Therapeutics, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Symbravo’s own FDA approval (NDA 215431) are listed, never a generic. Some codes belong to companies that repackage Symbravo: it is the same medicine in a different package.
What a Generic Symbravo Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Symbravo as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Symbravo”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Symbravo
Is there a generic for Symbravo right now?
No. As of October 9, 2026 no generic meloxicam and rizatriptan is listed for sale in the FDA NDC Directory.
When will Symbravo go generic?
May 2040 is the expected month, and that is probable but not certain. It is when Symbravo’s patent 12,128,052 ends. That patent covers a way of using it, and once it ends, generics should be able to go on sale as soon as the FDA approves them. The last listed patent runs to March 2045, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge.
Will generic meloxicam and rizatriptan be the same as Symbravo?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic, which would take the $122.64 pharmacies pay per tablet for Symbravo today to about $84.62. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Symbravo?
Not yet. The FDA Orange Book lists no approved generic version of Symbravo.
When does the Symbravo patent expire?
The FDA Orange Book lists 96 patents for Symbravo; the last runs to March 2045. The one behind the expected month is patent 12,128,052, which ends in May 2040. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (May 2040) weighs all of that.
Has anyone challenged the Symbravo patents?
Yes. The first patent challenge to Symbravo reached the FDA in June 2025, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
How much does Symbravo cost now?
Pharmacies paid about $122.64 per tablet for Symbravo 20-10 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected May 2040 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- RexultiBrexpiprazoleDuring 2029
- iDose TRTravoprostFebruary 2031
- MytesiCrofelemerOctober 2031
- Abilify MyCiteAripiprazoleOctober 2033
- VafseoVadadustat2034 to 2035
- CypsedoCipepofolDuring 2037
About Symbravo
- Generic name meloxicam and rizatriptan
- How it is taken By mouth
- Company Axsome Therapeutics Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since June 2025 (FDA)
- More drugs Brand-name drugs starting with S
- Have a question? A pharmacist answers, free. Ask about Symbravo
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.